References
Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: the CHAMPS Study. Open Forum Infect Dis. 2019;6(4):ofz166. doi:10.1093/ofid/ofz166.
. Hepatitis C virus universal screening versus risk based selective screening during pregnancy. J Neonatal Perinatal Med. 2015;8(4):371-378.
. Increased risk for mother-to-infant transmission of hepatitis C virus among Medicaid recipients - Wisconsin, 2011-2015. MMWR Morb Mortal Wkly Rep. 2017;66(42):1136-1139.
. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204-1212.
. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21(Suppl 1):60-89.
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2019;4(2):127-134. doi:10.1016/S2468-1253(18)30343-1.
. Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57(RR-8):1-20.
. Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep. 2003;52(RR-1):1-36.
. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238-1246.
. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program [abstract 37]. In: Presented at the Liver Meeting 2016. Presented at the Liver Meeting 2016. San Francisco, CA; 2016.
. GARNET: high SVR rates following eight-week treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir for patients with HCV genotype 1b infection [abstract 163]. New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure, September 23-24, 2016. 2016.
. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65(11):1861-1870.
. Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf. 2015;6(1):20-31. doi:10.1177/2042098614564776.
. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat. 2002;9(3):235-241.
Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831-844.
. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2004;140(7):557-568.
. Hepatitis C infection and intrahepatic cholestasis of pregnancy: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(1):39-45.
. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data. Hepatology. 2016;63(2):437-444.
. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28(3):805-809.
. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med. 2011;171(3):242-248.
.